Biotechnol Healthc. 2006 Apr;3(2):21-6.
Biotechnology healthcare
Ed Silverman
PMID: 23424345 PMCID: PMC3571026
As more biologics aimed at larger patient populations come to market, the effectiveness and appropriateness of copayments comes into question. This classic cost-sharing tool - developed for an earlier era's less expensive products - may not work in the biotech era.